Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025

Vistagen Therapeutics, Inc.

2026-Q2 EPS reported -$1.02 revenue$502,000

Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.
PALISADE-3 Phase 3 trial of fasedienol for social anxiety disorder completed; topline data expected by Q4 2025.
PALISADE-4 Phase 3 trial topline expected H1 2026; same public speaking challenge design.
Cash, equivalents, and marketable securities $77.2M as of Sep 30, 2025.
Paul Edick appointed to board of directors, effective October 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.